News coverage about Veracyte (NASDAQ:VCYT) has been trending somewhat positive on Wednesday, Accern reports. The research group identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Veracyte earned a media sentiment score of 0.10 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.5268952619817 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Veracyte (NASDAQ VCYT) traded down $0.03 during trading hours on Wednesday, hitting $6.12. 14,214 shares of the stock traded hands, compared to its average volume of 112,370. The company has a market cap of $201.18, a price-to-earnings ratio of -7.52 and a beta of 1.63. The company has a quick ratio of 4.86, a current ratio of 5.19 and a debt-to-equity ratio of 0.59. Veracyte has a 12 month low of $5.75 and a 12 month high of $9.80.
VCYT has been the subject of several analyst reports. BTIG Research set a $13.00 price target on shares of Veracyte and gave the stock a “buy” rating in a report on Monday, November 20th. Zacks Investment Research upgraded shares of Veracyte from a “sell” rating to a “hold” rating in a research note on Friday, November 10th. Janney Montgomery Scott lowered shares of Veracyte from a “buy” rating to a “neutral” rating in a research note on Tuesday, November 7th. Piper Jaffray Companies lowered shares of Veracyte from an “overweight” rating to a “neutral” rating in a research note on Tuesday, November 7th. Finally, Leerink Swann lowered their price objective on shares of Veracyte from $12.00 to $9.00 and set an “outperform” rating for the company in a research note on Tuesday, November 7th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $11.85.
COPYRIGHT VIOLATION NOTICE: “Veracyte (VCYT) Receives Daily News Sentiment Rating of 0.10” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.com-unik.info/2018/02/07/veracyte-vcyt-receives-daily-news-sentiment-rating-of-0-10.html.
Veracyte, Inc is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis.
Receive News & Ratings for Veracyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veracyte and related companies with MarketBeat.com's FREE daily email newsletter.